Lloyd Sanders, previously with Myriad Genetics, has joined Epic Sciences as CEO.
Murali Prahalad, who had the gig for six years, stepped down to pursue other opportunities, according to a March 25 news release. But he’ll remain involved with Epic as a board member.
Sanders was previously the president of the oncology segment of molecular diagnostics company Myriad Genetics. Prior to this, he was the chief operating officer of Dey Pharma, a division of Mylan, best known for the EpiPen brand.
Epic’s portfolio of tests guide cancer doctors deciding on a treatment path, including a test on the market for advanced prostate cancer.
“The trajectory has been set for significant commercial growth through Epic’s portfolio of high-value liquid biopsy tests and expansion into breast cancer, immuno-oncology and global markets,” said Chairman Gregory T. Lucier, in a statement.
Last September, Epic raised a $52 million series E round.